CBS 2019
CBSMD教育中心
中 文

Cardio-Oncology

Abstract

Recommended Article

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs Apixaban to Prevent Venous Thromboembolism in Patients with Cancer Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer Long-Term Outcomes of Patients With Mediastinal Radiation–Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement Drug-Drug Interactions of Common Cardiac Medications and Chemotherapeutic Agents Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients
|<< 1 2 3 4 5 >>|

Original Research2020 Jul 27.

JOURNAL：Neuroendocrinology. Article Link

Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications

M Liu, E Armeni, S Navalkissoor et al. Keywords: adenosine; arthritis; ticagrelor vs. clopidogrel; osteoarthritis

ABSTRACT

BACKGROUND - Cardiac metastases (CM) from neuroendocrine tumours (NET) are rare, however with the introduction of new molecular imaging modalities, such as 68Ga-DOTATATE PET-CT for NET diagnosis and re-staging, they are now identified more frequently. This study presents a single-institution experience on the NET CM characteristics, management and prognostic implications.


METHODS - Between January 1998 and January 2020, 25 NET patients with CM were treated in our Unit. A retrospective review of electronic records was performed. Overall survival (OS) was assessed by the Kaplan-Meier method. Cox regression models were used to evaluate the association of various clinical variables with OS.


RESULTS - The median age in the NET CM cohort was 64 years, with small intestine being the most common primary (84%). Nearly half of the patients suffered either from shortness of breath (48%) or had palpitations (12%). Peptide Receptor Radionuclide Therapy (PRRT) was applied in more than half of the patients (64%), who had an improved-trend for a longer median OS compared to those patients who did not receive PRRT (76.0 vs. 14.0 months, p = 0.196). The multivariate analysis demonstrated that concomitant skeletal or pancreatic metastases, as well as N-terminal Pro-B-type Natriuretic Peptide (NT pro-BNP) > 2 × upper limit of normal (ULN) were independent poor prognosticators.


CONCLUSIONS - Clinical features of NET CM ranged from asymptomatic patients to heart failure. Concomitant bone or pancreatic metastases and NT pro-BNP levels > 2 ULN predicted shorter survival time. PRRT serves as a feasible therapy with promising survival benefits, however more data are needed.


© 2020 S. Karger AG, Basel.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top